Relationship between the ABO Blood Group and the COVID-19 Susceptibility, Hacker News

Jiao Zhao , ( Yan ) Yang (Han-Ping Huang ) , Dong ) Li , Dong-Feng Gu , Xiang- Feng Lu , Zheng Zhang , Lei Liu , Ting Liu

Yu-Kun Liu , Yun-Jiao He , Bin Sun , Mei-Lan Wei , Guang-Yu Yang ,

View ORCID Profile Xinghuan Wang Li Zhang , Xiao-Yang Zhou , Ming-Zhao Xing ,

View ORCID Profile Peng George Wang

doi: https: / /doi.org/ (/ . .

OBJECTIVE To investigate the relationship between the ABO blood group and the COVID – susceptibility. DESIGN The study was conducted by comparing the blood group distribution in 2, patients with COVID – 25 confirmed by SARS-CoV-2 test from three hospitals in Wuhan and Shenzhen, China with that in normal people from the corresponding regions. Data were analyzed using one-way ANOVA and 2-tailed χ2 and a meta-analysis was performed by random effects models. SETTING Three tertiary hospitals in Wuhan and Shenzhen, China. PARTICIPANTS A total of 1, patients with COVID – , including dead cases, from Wuhan Jinyintan Hospital, Wuhan, China were recruited. Another and 823 patients with COVID – were respectively recruited from Renmin Hospital of Wuhan University, Wuhan and Shenzhen Third People’s Hospital, Shenzhen , China. MAIN OUTCOME MEASURES Detection of ABO blood groups, infection occurrence of SARS-CoV-2, and patient death RESULTS The ABO group in normal people in Wuhan showed a distribution of . (%, 33 (%, 9.) % and 60. % for A, B, AB and O, respectively, versus the distribution of %, 42) %, . (% and

% for A, B, AB and O, respectively, in COVID – patients from Wuhan Jinyintan H. ospital. The proportion of blood group A and O in COVID – 25 patients were significantly higher and lower, respectively, than that in normal people (both P

Funding Statement

Not Applicable Author Declarations

All relevant ethical guidelines have been followed; Any necessary IRB and / or ethics committee approvals have been obtained and details of the IRB / oversight body are included in the manuscript. (Yes)

All necessary patient / participant consent has been obtained and the appropriate institutional forms have been archived. (Yes) I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance) . (Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist (s) and other pertinent material as supplementary files, if applicable. (Yes)